Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT

Main Article Content

Joseph F. Merola
Alice B. Gottlieb
Jennifer Soung
Philip Hampton
Andreas Pinter
Melinda Gooderham
Akimichi Morita
Sarah Kavanagh
Nancy Cross
Susanne Wiegratz
Carle Paul

Keywords

psoriasis, bimekizumab, long-term efficacy, high-impact areas, scalp, nail, palmoplantar, quality of life, clinical trial

Abstract

 


 

References

1. Merola JF et al. Dermatol Ther 2018;31:e12589

2. Cashman MW et al. Clin Dermatol 2010;28:420–5

3. Adams R et al. Front Immunol 2020;11:1894

4. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747

5. Reich K et al. Lancet 2021;397:487–98, NCT03370133

6. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884

7. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992

8. Merola JF et al. Presented at EADV 2023; P2547

9. Strober B et al. Br J Dermatol 2023;188:749–59, NCT03598790

10. European Medicines Agency. Bimekizumab Summary of Product Characteristics. 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-productinformation_en.pdf [Accessed September 2024].

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>